COMPANY:

Genetic Technologies

"Genetic Technologies Limited...is pleased to announce the Company has negotiated a partnership agreement with Chicago based CancerIQ...GeneType will be CancerIQ’s first lab partner solely focused on polygenic-integrated clinical risk prediction. GeneType’s focus has always been population healthcare, but until recently healthcare systems have been largely concentrating on hereditary cancer risk."

"Genetic Technologies Limited...is pleased to announce the global launch of the geneType™ Risk Assessment portfolio on our wholly owned EasyDNA platform currently selling in 42 countries...The availability of geneType™ on EasyDNA’s consumer platform will accelerate global access."

"Genetic Technologies Limited...announced the introduction of geneType’s suite of genetic risk assessment tests to Canada and New Zealand. Dovetailing geneType’s recent expansion to the US market under its partnership with health and wellness technology leader Stayhealthy, Inc ('Stayhealthy'), the company is expanding its international presence four-fold in the second quarter of 2024."

"Genetic Technologies Limited...is pleased to share the power of the geneType test in identifying risk and improving the health of populations worldwide...GeneType is revolutionizing healthcare with its pioneering, non-invasive Multi-Risk Test, designed to uncover hidden risks of common yet serious diseases. This state-of-the-art test identifies individuals at elevated risk for a range of cancers, including breast, ovarian, pancreatic, prostate, colorectal, and melanoma, as well as cardiovascular diseases and metabolic conditions like Type 2 diabetes."

"Genetic Technologies Limited...is pleased to announce the Company has released its novel Comprehensive Risk Assessment test that covers 100% of women at risk of developing breast and ovarian cancer. The innovative test, available to all women above the age of 30, assesses a woman’s risk of cancer due to hereditary, including those with common gene mutations, and sporadic disease."

"Genetic Technologies Limited...is pleased to announce the Company has established a precision oncology division and announced its highly anticipated portfolio of new diagnostic tests under its geneType precision oncology brand."

"Genetic Technologies Limited...is pleased to announce the company is establishing a clinical implementation study with breast imaging centres across New York, Miami and Houston."

"Genetic Technologies Limited...is pleased to announce the development of the Company’s most advanced risk assessment test for serious diseases, building on the success of the Comprehensive Hereditary Breast and Ovarian Cancer (HBOC) test."

"Genetic Technologies (GTG)...provide details of a series of recent transformative initiatives. Our commitment to advancing early detection of serious diseases through a revolutionary non-invasive saliva test has been recently showcased on several national Australian media channels."

"Genetic Technologies Limited...announce that a Medical Research Future Fund (MRFF) Genomics Health Futures Mission Grant has been awarded to a group of renowned national and international research and charity organizations."

"Genetic Technologies Limited...proudly announces a groundbreaking development. The expanded geneType Multi-Risk Test is now readily accessible for order in Australia, marking a significant milestone in the journey to redefine preventative healthcare....Today, with immense pride, we share the news that these innovations, including assessments for Pancreatic Cancer, Melanoma...have been authorized for sale in Australia by National Association of Testing Authority (NATA). This expanded genetic test now offers a comprehensive evaluation of risk for a total of nine individual serious diseases, all extracted from a single, simple saliva sample."

"Genetic Technologies Limited...is pleased to announce the publication of a research paper in 'The Prostate' validating the utilisation of geneType Prostate Cancer Risk Assessment Test in the identification of men who are at increased risk of this serious disease....The study demonstrated that geneType could enable a more targeted approach to Prostate Specific Antigen (PSA) screening of high-risk men – ultimately providing far greater utility of the PSA screening test."

"Genetic Technologies Limited...announce the initiation of phase 2 of the rollout plan for the geneType Multi-Test. The expanded panel now includes three new diseases taking the total number of individual risk assessments included in the geneType Multi-Test to nine, all from the one simple saliva sample."

P=NA | N=NA| "Genetic Technologies Limited...is pleased to announce the publication of another research paper supporting the utilisation of geneType Breast Cancer Risk Assessment Test in the peer-reviewed journal Cancer Prevention Research....GeneType improved discrimination and risk categorization when compared to one of the most well-known models, the Breast Cancer Risk Assessment Tool (BCRAT). Over a five-year period, at-risk women classified ≥3% 5-year risk by geneType had a 1.829 times increased incidence of breast cancer compared to the general population, which was higher than the 1.413 times increased incidence for women classified ≥3% by BCRAT."

"Genetic Technologies Limited...is pleased to announce the Company will launch a ‘World First’ Comprehensive Risk Assessment Test which evaluates a women’s risk of developing Breast and/or Ovarian Cancer either from a hereditary genetic mutation or from the far more common familial or sporadic cancer....This test will be launched via our Business to Business (‘B2B’) and Consumer Initiated Testing (‘CIT’) channels in the United States. The Comprehensive Risk Test will be showcased at the BRCA 2023 Symposium in Montreal in early May."

"Genetic Technologies said on Tuesday that its lab has received regulatory approvals in Australia and the US that will enable the commercial launch of its GeneType risk-assessment test for certain cancers and other diseases in those markets...The Melbourne, Australia-based company said that its lab has recently received accreditation from Australia's National Association of Testing Authorities and CLIA certification from the US Centers for Medicare & Medicaid Services, clearing the way for a commercial release of the test for healthcare professionals in the two countries this week."